Suggested remit: To appraise the clinical and cost effectiveness of talazoparib with enzalutamide within its marketing authorisation for treating hormone-relapsed metastatic prostate cancer in people who have not had prior systemic treatment.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- STA Standard
- ID number:
- 4004
Provisional Schedule
- Expected publication:
- 15 October 2025
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- Pfizer
- Others
- Department of Health and Social Care
- NHS England
- Heath Technology Wales
- Patient carer groups
- Prostate Cancer Research
- Tackle Prostate Cancer
- Professional groups
- Association of Cancer Physicians
- British Uro-Oncology Group
- Cancer Research UK
- Prostate Cancer Advisory group
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Astellas Pharma (enzalutamide)
- Janssen (abiraterone)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 August 2025 | Committee meeting: 1 |
| 15 July 2024 | Invitation to participate |
| 17 June 2024 - 01 July 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 17 June 2024 | In progress. In progress |
| 23 August 2023 | Suspended. Please note the company has informed NICE that it will not provide an evidence submission for this appraisal at this time. Therefore, we are suspending the appraisal while we consider the next steps. |
| 31 July 2023 - 04 August 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1234 |
| 10 July 2023 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early September 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 04 November 2022 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. Please note that following on from information received from the company, the timelines for this appraisal will be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course. NICE will continue to monitor any developments and will update interested parties as and when the situation changes. |
| 02 September 2022 - 30 September 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 02 September 2022 | In progress. Scoping commenced |
| 05 August 2022 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late November 2022. |
| 12 April 2022 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. |
For further information on our processes and methods, please see our CHTE processes and methods manual